$283 Million is the total value of Aisling Capital Management LP's 21 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $101,216,000 | -64.4% | 6,068,125 | 0.0% | 35.71% | -37.0% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $30,065,000 | -8.3% | 1,472,331 | 0.0% | 10.61% | +62.2% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $22,437,000 | +14.5% | 1,025,000 | 0.0% | 7.92% | +102.7% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $21,599,000 | -14.5% | 2,541,009 | 0.0% | 7.62% | +51.3% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $17,066,000 | -22.7% | 2,834,910 | 0.0% | 6.02% | +36.7% | |
| HRMY | Sell | Harmony Biosciences Holdings Inc. (HRMY) | $15,155,000 | -33.3% | 355,415 | -40.0% | 5.35% | +18.0% |
| TALS | Talaris Therapeutics Inc. (TALS) | $10,442,000 | +12.8% | 682,923 | 0.0% | 3.68% | +99.5% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $9,225,000 | -19.2% | 634,455 | 0.0% | 3.25% | +42.9% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $8,954,000 | +22.6% | 1,332,485 | 0.0% | 3.16% | +117.0% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $8,033,000 | -40.3% | 1,691,151 | 0.0% | 2.83% | +5.7% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $7,576,000 | +14.8% | 886,075 | 0.0% | 2.67% | +103.1% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $7,105,000 | -6.6% | 1,043,267 | 0.0% | 2.51% | +65.3% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $5,951,000 | -37.8% | 798,757 | 0.0% | 2.10% | +10.1% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $5,377,000 | -25.8% | 1,205,511 | 0.0% | 1.90% | +31.3% | |
| AVRO | AVROBIO, Inc. (AVRO) | $3,888,000 | -31.0% | 1,009,779 | 0.0% | 1.37% | +22.1% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $2,986,000 | -43.8% | 3,142,857 | 0.0% | 1.05% | -0.6% | |
| OBSV | ObsEva SA (OBSV) | $2,759,000 | -36.0% | 1,386,338 | 0.0% | 0.97% | +13.1% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $1,278,000 | -34.7% | 2,718,226 | 0.0% | 0.45% | +15.6% | |
| BCEL | Atreca Inc. (BCEL) | $1,175,000 | -51.3% | 387,653 | 0.0% | 0.42% | -13.9% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $1,053,000 | -54.5% | 288,571 | 0.0% | 0.37% | -19.5% | |
| Nabriva Therapeutics plc (NBRV) | $114,000 | -49.8% | 191,028 | 0.0% | 0.04% | -11.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.